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Abstract
Purpose To evaluate HPV and  p16ink4a status as prognostic factors in patients with invasive vulvar cancer.
Methods Retrospective analysis of disease-free (DFS) and disease-specific survival (DSS) of patients with invasive vulvar 
cancer at a single tertiary care center. Histology, HPV and  p16ink4a status were evaluated in the context of a global multicenter 
trial. Logistic regression models were performed to identify the impact of  p16ink4a positivity.
Results 135 patients were included in the analysis. 32 (23.7%) showed a  p16ink4a expression of over 25%. Disease-free and 
disease-specific survival was longer in  p16ink4a positive patients (23 vs. 10 months, p = 0.004, respectively, 29 vs. 21 months, 
p = 0.016). In multivariate analysis,  p16ink4a positivity was an independent parameter for DFS (p = 0.025, HR: 2.120 (1.100–
4.085)), but not for DSS (p = 0.926, HR: 1.029 (0.558–1.901), in contrast to age and tumor stage.
Conclusions Age and tumor stage negatively affect survival. However, disease-free survival is significantly longer in patients 
with  p16ink4a positive invasive vulvar cancer.
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Introduction
Over the past two decades, the incidence rates of invasive 
vulvar cancer, which is responsible for about 5% of all 
gynecological cancers, increased continuously. Especially 
in women younger than 50 years of age, the incidence rates 
almost tripled over the past decades [1–3]. Especially the 
influence of HPV-positivity and  p16ink4a expression on 
patient’s outcome is the main focus nowadays [4]. In the 
largest multicenter study, including 1709 cases in 39 coun-
tries from five continents, de Sanjosé et al. were able to 
identify Human papilloma virus (HPV) infection in approx-
imately 25% of invasive vulvar cancer (IVC) cases [5, 6]. 
Similar findings could be shown in a Scottish single-center 
study, where Wakeham et al. reported a prognostic benefit 
on the clinical outcome of HPV-positive vulvar cancer [7]. 
In a meta-analysis including 7.721 patients, Zhang et al. 
supported these results [8]. In a recently published Dutch 
study, Hinten et al. described the combination of HPV and 
 p16ink4a positivity as a favorable prognostic factor in IVC 
[9].  P16ink4a overexpression, defined as at least 25% of cells 
with nuclear or cytoplasmic staining, is an indicator of 
HPV associated tumors. Transient HPV infections can be 
excluded and only tumors with HPV as the primary cause 
of the oncologic process remain [10–12]. We present the 
clinical Austrian data nested in the global multicenter study 
and combined this with clinical outcome data. While the 
presence of lymph node metastasis is the most important 
predictive parameter for survival, the  p16ink4a status may 
strongly influence the patient’s outcome, which is already 
established in oropharyngeal cancer [7]. Age at diagnosis, 
initial treatment option, histological groups, clinical out-
come, recurrence and regression rates and patient’s comor-
bidities were evaluated retrospectively. The aim of the study 
was to evaluate the  p16ink4a positivity and HPV status on the 
clinical outcome in IVC.
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Material and methods
Austria was one of 39 countries participating in the inter-
national collaborative study [4]. Patients diagnosed with 
primary IVC at the Department for Gynecological Oncol-
ogy of the Medical University of Vienna between 1995 and 
2012 were enrolled in this cross-sectional period-preva-
lence study on archival specimens. The paraffin-embedded 
blocks of archival histological specimens were sent to the 
study center at the Institut Catalan di Oncologia (ICO) in 
Barcelona for further evaluation. Initially, 204 samples of 
vulvar neoplasia and control samples were sent to Barce-
lona for histopathological evaluation. 177 samples were 
classified as suitable for HPV-testing. According to proto-
col, specimen were reviewed and classified, HPV-type and 
expression of the tumor suppressor protein  p16ink4a was 
evaluated. A sensitive assay, using SPF10 broad spectrum 
primers PCR and DEIA (DNA enzyme immunoassay) was 
used for HPV–DNA detection. Positive samples were sub-
sequently analyzed by SPF10 PCR/DEIA/LIPA25 (RHA 
Kit HPV SPF10-LiPA25, version 1 by Labo Biomedical 
Products, Rijswijk, The Netherlands), which is a reverse 
hybridization technique that detects 25 high-risk (HR) and 
low-risk (LR) HPV types (6, 11, 16, 18, 31, 33, 34, 35, 
39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 
70, 74). Furthermore, IVC cases were tested for cyclin-
dependent kinase-4 inhibitor  (p16ink4a), which is reported 
to be overexpressed in at least 90% of HPV-related VIN 
and IVC cases. Therefore,  CINtec® PLUS Cytology Kit by 
Roche (clone E6H4, ROCHE MTM Laboratories, Heidel-
berg, Germany) was used to detect  p16ink4a in the invasive 
vulvar cancer cases. A case was considered to be positive 
if more than 25% of invasive cancer cells showed a diffuse 
overexpression [4, 5, 13]. The clinical data were collected 
and evaluated retrospectively at our institution. Follow-
up and clinical outcome were available for 135 eligible 
patients. Data was collected from June 1993 until January 
2016. Before the study was initiated, it was approved by 
the Ethics Committee of the Medical University of Vienna 
(IRB approval number: 1997/2015, approved on May 20th, 
2016). Since this study was a retrospective analysis, no 
informed consent from patients was required by the eth-
ics committee. Patient’s records were anonymized prior 
to analysis.
IVC management
All patients included were managed by gynecologic oncol-
ogists. Predefined uniform criteria for surgical procedure 
terminology, pathologic variables, and sites of recurrence 
were used. Based on the FIGO 2009 classification system, 
disease staging was performed [14]. Depending on the 
tumor’s extent and the physician’s assessment, patients 
underwent surgery. In case of positive lymph nodes, adju-
vant radiotherapy was performed.
For the first 2 years, clinical examination was performed 
every 3 months, followed by 6 months intervals until the 
completed fifth year, then by annually consultations. At 
every follow up check, the patient received a vulvoscopy, 
vagino-rectal palpation and groin inspection. Furthermore, 
serum squamous cell carcinoma antigen (SCC) was evalu-
ated. Biopsy and or computed tomography were performed 
when recurrent disease was suspected. Based on post-
mortem results, patient’s death and causes of death were 
documented.
Statistical analysis
Patient’s data was divided in two different groups (group1/
group2), assuming that cases in which HPV–DNA is 
detected without overexpression of  p16ink4a could repre-
sent a transient infection with no role in carcinogenesis. 
Group 1 represented patients with HPV-positive and HPV-
negative IVC with a  p16ink4a expression in less than 25% 
(< 25% = negative) and group 2 consisted of HPV-positive 
and HPV-negative IVC with a concomitant overexpression 
of  p16ink4a (≥ 25%). Values are shown as mean values with 
standard deviation (SD). To compare HPV-positivity with 
clinic-pathological parameters, t tests were performed. P 
values of < 0.05 were considered statistically significant. 
With respect to overall and disease-free survival, differ-
ences between groups were tested using the log-rank test 
and are presented as Kaplan–Meier survival curves. Mul-
tivariable analysis was performed using a Cox regression 
model including patient’s age (mean, IQR),  p16ink4a expres-
sion and tumor stage (FIGO III and IV vs. FIGO I and FIGO 
II) as independent variables. Furthermore, FIGO I and II 
adapted analysis was performed via t test and is presented 
as Kaplan–Meier survival curves as well. Statistical analy-
ses were performed using SPSS 25.0 for MAC (SPSS 25.0, 
IBM Inc., Armonk, NY). Collected data: age at diagnosis, 
histopathological grading, initial therapy, HPV-subtype 
analysis,  p16ink4a expression, FIGO classification, disease-
free survival, disease-specific survival, nicotine abuse, coex-
istent lichen sclerosus or VIN, previous malignant disease, 
comorbidities.
Results
135 patients with invasive vulvar cancer were analyzed. 
Patients were grouped by their  p16ink4a status to exclude 
transient HPV infections (Table 1). Patient characteris-
tics are shown in Table 2. The median age at diagnosis of 
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patients in group 1 was 71, ranging from 58–84 years (IQR), 
whereas patients from group 2 were by median 64 years of 
age (IQR: 47–81 years). Patients of group 2 were signifi-
cantly younger (p < 0.001). In 30 (22.2%) of the evaluated 
histological specimen, HPV was detected. HPV 16 was 
the primarily diagnosed HPV-subtype and detected in 27 
cases (77%). HPV 31 was detected in two cases (6.7%) and 
HPV 33 (3.3%) in one. In 20 (66.7%) of those HPV-positive 
cases, an overexpression (≥ 25%) of the tumor-suppressor-
protein  p16ink4a was detected. Contrary, only 12 (11.4%) of 
HPV-negative IVC presented an overexpression of  p16ink4a 
(Table 1).
A coexistent lichen sclerosus was detected in 6 (4.4%) 
cases, all of them were HPV-negative. FIGO stages were 
well balanced between both groups (p = 0.501). Further sub-
group analysis, only including patients at FIGO stage I and 
II was performed.
76 (56.3%) patients suffered at least one relapse. Mean 
disease-free survival (DFS) in group 1 was 10 months (IQR: 
5–36), whereas patients from group 2 had a relapse after 
23 months (IQR: 4–65.5), p = 0.004 (Fig. 1a). Similar results 
could be shown regarding the patient’s disease-specific sur-
vival. Patients of group 2 lived in average 29 months after 
primary diagnosis (IQR: 4–116.5), whereas patients of 
group 1 only survived 21 months (IQR: 8–87), p = 0.016 
(Fig. 1b). In multivariate analysis,  p16ink4a positivity still 
could be verified as an independent parameter regarding 
disease-free survival (p = 0.025, HR: 2.120 (1.100–4.085)) 
but not disease-specific survival (DSS) (p = 0.926, HR: 
1.029 (0.558–1.901)). Results on multivariate analysis are 
presented in Table 3.
To have a closer look at patients with a favorable progno-
sis, FIGO stage I and II were analyzed separately (Table 4). 
Patients of group 1 (n = 80, 77.7%), still were significantly 
older (mean: 70.5 years (IQR: 57.4–83.6)), than patients 
of group 2 (mean: 63.1 years (IQR:46.0–79.5)), p = 0.028. 
Disease-free survival of group 2 still was significantly 
longer than in group 1; p = 0.011 (Fig. 1c). We obtained 
similar results regarding DSS; p = 0.020 (Fig. 1d). Group 
2 could still be verified as an independent prognostic fac-
tor in multivariate analysis regarding DFS (p = 0.036, HR: 
2.151 (1.053–4.393)), but not concerning DSS (p = 0.774, 
HR: 1.111 (0.541–2.285), Table 5).
Furthermore, for sensitivity analysis, patients aged 
80 years, or more were excluded in the subgroup analysis of 
FIGO stages I and II. Excluding the old ages as a possible 
Table 1  Group classification depending on HPV and  p16ink4a expres-
sion in patients with invasive vulvar cancer
Group 1:  p16ink4a < 25%; Group 2:  p16ink4a ≥ 25%
Group 1
n = 103 (76.3%)
Group 2
n = 32 (23.7%)
HPV-positive,  p16ink4a ≥ 25% 0 (0) 20 (62.5)
HPV-negative,  p16ink4a ≥ 25% 0 (0) 12 (37.5)
HPV-positive,  p16ink4a < 25% 10 (9.7) 0 (0)
HPV-negative,  p16ink4a < 25% 93 (90.3) 0 (0)
Table 2  Patient’s characteristics
Group 1: p16ink4a < 25%; Group 2: p16ink4a ≥ 25%
a t test, bChi-square test, clog-rank
Group 1
n = 103 (76.3%)
Group 2
n = 32 (23.7%)
p value
Age in years, median (IQR) 71 (58–84) 64 (47–81) 0.0011
Initial treatment 0.5472
 Surgery (%) 97 (94.2) 31 (96.9)
 Radiation (%) 6 (5.8) 1 (3.1)
FIGO
 I&II (%) 80 (77.7) 23 (71.9)
 III&IV (%) 23 (22.3) 9 (28.1)
FIGO I&II vs. FIGO III&IV 0.5012
Grading 0.4922
 1 (%) 37 (36) 8 (25)
 2 (%) 56 (54) 21 (66)
 3 (%) 10 (10) 3 (9)
Smoking n = 72 n = 19 0.4212
 Yes (%) 13 (18) 5 (26)
 No (%) 59 (82) 14 (74)
Disease-free survival in months, median (IQR) 10 (5–36) 23 (4–65.5) 0.0043
Disease-specific survival in months, median (IQR) 21 (8–87) 29.5 (4–116.5) 0.0163
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Fig. 1  Kaplan Meier curves on disease-free and overall survival
Table 3  Cox regression analysis 
of predictive markers in patients 
with invasive vulvar cancer





p value HR (95% CI) p value HR (95%CI)
p16ink4a ≥ 25% 0.025 2.120 (1.100;4.085) 0.926 1.029 (0.558;1.901)
Age 0.010 1.024 (1.006;1.043)  < 0.001 1.060 (1.038;1.082)
FIGO 0.984 1.007 (0.511;1.982) 0.001 2.413 (1.404;4.147)
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bias, the difference between both groups for DFS and DSS 
remained statistically significant (p = 0.010 and p = 0.048, 
respectively).
Discussion
In our dataset of 135 IVC, survival indicators, DFS and 
DSS, were significantly longer in  p16ink4a positive patients. 
In multivariate analysis,  p16ink4a positivity remained an inde-
pendent favorable prognostic factor for DFS, whereas DSS 
was not affected. This study was a clinical sub-analysis of 
an international collaborative study, initiated by de Sanjosé, 
where 39 countries including our institution participated in 
that cross-sectional period-prevalence study on archival 
specimens, where more than 2000 IVC were histopathologi-
cal analyzed [4]. The main advantage was the single-center 
analysis, using highly standardized and specified protocols. 
During a prolonged observational period of more than 
10 years, patients were observed by a single group of special-
ized, oncologic gynecologists, providing the high quality of 
patient care and precise detection rate of IVC relapses. The 
study setting provided a reliable assessment of histology, 
HPV and  p16ink4a analysis linked to single-center clinical 
data with a long observational period, although retrospective 
design is an undeniable limitation. Due to the retrospec-
tive design, only data on initial smoking behavior are avail-
able, no continuous data were collected. In addition, data on 
vaccination status and quality of life are not available. Our 
results support the recent published study by Arians et.al., 
where  p16ink4a overexpression, which is as a marker for per-
sistent HPV infections, seems to have a beneficial influence 
on disease-free and disease-specific survival of patients with 
IVC [15–17]. To be comparable with the recently published 
data, we replicated the group assignments and analysis 
according to Hinten’s recently published results. The dif-
ference in age of our patient cohorts was smaller than in the 
Dutch publication (71 vs. 64 years, compared to Hinten’s 
72 vs. 55 years). Therefore, we can assume a similar state 
of health in both observed groups [9]. To evaluate the role 
of HPV and related markers, a sub-analysis of small tumors 
(FIGO I and II), was performed to reduce potential bias due 
to poor prognosis related to advanced stage that could be 
independent of HPV status. In the Dutch paper there was an 
uneven distribution of tumor stage with more FIGO stage 
III and IV disease in the  p16ink4a negative cohort which is 
a clinically relevant bias. 45% patient’s with  p16ink4a nega-
tive IVC were diagnosed in higher FIGO stage III and IV 
(p = 0.001) [9]. In our analysis, the FIGO stages at diagnosis 
(FIGO I and II vs. FIGO III and IV) were very well balanced 
Table 4  Patient’s 
characteristics, subgroup 
analysis FIGO stage I and II 
only
Group 1:  p16ink4a < 25%; Group 2:  p16ink4a ≥ 25%
a t test, bChi-square test, clog-rank
Group 1
n = 80 (77.7%)
Group 2
n = 23 (22.3%)
p value
Age in years, median (IQR) 70.5 (57.4–83.6) 63.1 (46–79.5) 0.0281
Initial treatment 0.8982
 Surgery (%) 76 (95) 22 (96)
 Radiation (%) 4 (5) 1 (4)
Grading 0.3212
 1 (%) 34 (36) 6 (25)
 2 (%) 40 (54) 14 (66)
 3 (%) 6 (10) 3 (9)
Smoking n = 72 n = 19 0.4212
 Yes (%) 13 (18) 5 (26)
 No (%) 59 (82) 14 (74)
Disease-free survival in months, median (IQR) 11.5 (6–38.5) 38(8–74) 0.0113
Disease-specific survival in months, median (IQR) 37.5(10–94.7) 46(10–119) 0.0203
Table 5  Cox regression analysis 
of predictive markers in patients 
with invasive vulvar cancer with 





p value HR (95% CI) p value HR (95%CI)
 p16ink4a ≥ 25% 0.036 2.151 (1.053;4.393) 0.774 1.111 (0.541;2.285)
 Age 0.016 1.025 (1.005;1.045)  < 0.001 1.070 (1.043;1.098)
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(Table 2, p = 0.501). Although patients with  p16ink4a posi-
tive IVC were on average seven years younger than  p16ink4a 
negative controls and the first recurrence occurred after an 
average of 2 years instead of one year, in multivariate analy-
sis DSS depends on younger age and lower FIGO stage but 
not on  p16ink4a status. Therefore, further research has to be 
done on data of relapse in IVC. Since there is no appropri-
ate screening for VIN and IVC, elimination of HPV-related 
tumors is possible in countries with a good coverage of HPV 
vaccination [7, 13, 18–22]. In conclusion, higher age and 
tumor stage negatively affect survival. However, disease-free 
survival is significantly longer in patients with  p16ink4a posi-
tive invasive vulvar cancer. There is a caveat which needs 
further investigation: In case of a relapse, the mortality of 
the initially prognostic favorable  p16ink4a positive invasive 
vulvar cancer appears to be worse.
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